Inclisiran mechanism described as which?

Enhance your knowledge of antihyperlipidemics and lipid management. Study with multiple choice questions and detailed explanations. Ace your test!

Multiple Choice

Inclisiran mechanism described as which?

Inclisiran is an siRNA-based therapy that reduces PCSK9 production. It uses RNA interference to target PCSK9 mRNA in liver cells, leading to degradation of the mRNA and less PCSK9 protein being made. With lower PCSK9 levels, more LDL receptors remain on hepatocytes to clear LDL cholesterol from the blood, so LDL-C levels fall. This is different from monoclonal antibodies against PCSK9, which neutralize circulating PCSK9, or small-molecule inhibitors or gene-editing approaches. Inclisiran is delivered to the liver (often via GalNAc conjugation) and acts long-acting, allowing less frequent dosing.

Inclisiran is an siRNA-based therapy that reduces PCSK9 production. It uses RNA interference to target PCSK9 mRNA in liver cells, leading to degradation of the mRNA and less PCSK9 protein being made. With lower PCSK9 levels, more LDL receptors remain on hepatocytes to clear LDL cholesterol from the blood, so LDL-C levels fall. This is different from monoclonal antibodies against PCSK9, which neutralize circulating PCSK9, or small-molecule inhibitors or gene-editing approaches. Inclisiran is delivered to the liver (often via GalNAc conjugation) and acts long-acting, allowing less frequent dosing.

More practice questions